Biochem Pharmaceutical IndustriesPart Ix Profile
Key Indicators
- Authorised Capital ₹ 12.00 Cr
as on 29-10-2024
- Paid Up Capital ₹ 7.50 Cr
as on 29-10-2024
- Company Age 20 Year, 1 Month
- Last Filing with ROC 31 Mar 2016
- Open Charges ₹ 40.00 Cr
as on 29-10-2024
- Satisfied Charges ₹ 13.85 Cr
as on 29-10-2024
About Biochem Pharmaceutical IndustriesPart Ix
- CIN/LLPIN
U24230GJ2004PLC094323
- Company No.
094323
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
04 Nov 2004
- Date of AGM
04 Aug 2016
- Date of Balance Sheet
31 Mar 2016
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Biochem Pharmaceutical IndustriesPart Ix?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nitinkumar Parekh  | Director | 21-Dec-2011 | Current |
| Ganesh Nayak | Director | 21-Dec-2011 | Current |
| Deevyesh Radia | Director | 13-Jan-2015 | Current |
| Mayank Shah | Director | 04-Nov-2004 | Current |
| Bhavana Doshi | Director | 13-Jan-2015 | Current |
| Anilkumar Matai | Director | 10-Nov-2014 | Current |
Financial Performance and Corporate Structure Insights of Biochem Pharmaceutical IndustriesPart Ix.
Enhance accessibility to Biochem Pharmaceutical IndustriesPart Ix's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Biochem Pharmaceutical IndustriesPart Ix?
In 2016, Biochem Pharmaceutical IndustriesPart Ix had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Zydus Hospira Oncology Private LimitedActive 19 years 6 monthsGanesh Nayak and Nitinkumar Parekh are mutual person
_LIMITED.webp)
Organisation Of Pharmaceutical Producers Of IndiaActive 58 years 11 monthsAnilkumar Matai is a mutual person
_LIMITED.webp)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 08 Aug 2012 | ₹40.00 Cr | Open |
Union Bank Of India Limited Creation Date: 27 Apr 2006 | ₹5.25 Cr | Satisfied |
Union Bank Of India Creation Date: 10 Jan 2006 | ₹0.50 M | Satisfied |
How Many Employees Work at Biochem Pharmaceutical IndustriesPart Ix?
Unlock and access historical data on people associated with Biochem Pharmaceutical IndustriesPart Ix, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biochem Pharmaceutical IndustriesPart Ix, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biochem Pharmaceutical IndustriesPart Ix's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
